ZAI LAB LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.48 USD | +1.97% |
|
-9.05% | -46.69% |
| Apr. 11 | Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 | MT |
| Apr. 11 | Zai Lab Changes Record Date | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
14.2
USD
Average target price
54.12
USD
Spread / Average Target
+281.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.69% | 1.4B | |
| -4.17% | 86.99B | |
| +4.34% | 40.68B | |
| -23.70% | 28.61B | |
| +51.27% | 24.1B | |
| -4.99% | 17.37B | |
| -32.11% | 13.72B | |
| -5.10% | 12.49B | |
| -14.56% | 12B | |
| -3.22% | 7.94B |
- Stock Market
- Equities
- ZLAB Stock
- News Zai Lab Limited
- Zai Lab's Conversion of Secondary Listing in Hong Kong to Primary to Take Effect June 27; Shares Jump 5%
